We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mapping of Atherosclerotic Plaque Cells Predicts Future Risk of Stroke or Heart Attack

By LabMedica International staff writers
Posted on 21 Nov 2024
Print article
Image: Patients can be divided into three groups with different disease severity based on composition of smooth muscle cells in blood vessels (Photo courtesy of Melody Chemaly)
Image: Patients can be divided into three groups with different disease severity based on composition of smooth muscle cells in blood vessels (Photo courtesy of Melody Chemaly)

Atherosclerosis is the leading cause of cardiovascular diseases like heart attacks and strokes. Over many years, atherosclerotic plaques develop from the accumulation of blood lipids such as cholesterol in the innermost layer of blood vessels. As these plaques become unstable and rupture, blood clots can form, blocking the vessel or traveling to other organs, like the brain. This blockage prevents oxygen from reaching the tissues, leading to a stroke or heart attack. Mortality rates from cardiovascular disease have decreased over the past 50 years due to advancements in understanding disease mechanisms, improved preventive treatments, better diagnostics, and healthier lifestyle choices. Now, a new study has revealed that genetic traits play a role in determining the cellular makeup of atherosclerotic plaques, which influences the likelihood of these plaques causing strokes or heart attacks over time. This discovery could enhance future risk assessment and treatment strategies for patients with atherosclerosis.

Researchers at Karolinska Institutet (Stockholm, Sweden), along with colleagues, successfully mapped the relationship between genetic factors and the composition of different cell types in atherosclerotic plaques. Their research, published in the European Heart Journal, utilized tissue samples from patients with atherosclerosis, stored in a biobank. The researchers used this genetic data to categorize patients into three distinct groups. The first group, with the most severe profiles, typically includes patients who have already experienced a stroke. The second group consists of patients at lower risk, whose vessels contain plaques but have not resulted in a stroke. The third group falls between the other two and often has kidney disease alongside atherosclerosis.

The team has also found preliminary evidence suggesting that this genetic influence might apply to heart attacks as well. This new understanding of how genetics affect plaque cell composition could be integrated with advanced diagnostic imaging and AI to improve assessments of future stroke or heart attack risks and predict how patients might respond to different treatments. While the researchers have conducted similar studies for smaller cohorts in the past, this concept needs to be validated on a larger scale before it can be used in clinical practice. The team plans to continue working on these multi-modal studies to further develop this approach.

“Previous research has shown that heredity is important for the levels of cholesterol, other lipids and circulating immune cells in the blood, but now we see that heredity also affects the composition of smooth muscle cells in the blood vessels of atherosclerotic patients,” says Ljubica Matic, docent at the Department of Molecular Medicine and Surgery at Karolinska Institutet who led the study. “This can affect the development of atherosclerotic plaques, but also the tendency for the plaques to become unstable and cause a stroke.”

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.